Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
Date:2/28/2008

VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 9:00 a.m. ET on Tuesday, March 4, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Dick Anderson and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 566-5775 or (210) 234-0004. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 396-7637 or (203) 369-0522. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. MannKind to Present at the Wachovia 2008 Healthcare Conference
3. MannKind to Present at the Piper Jaffray Healthcare Conference
4. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. MannKind to Present at the UBS Global Life Sciences Conference
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
9. Pharmion Corporation Announces 2007 Operating Results
10. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
11. VLST Corporation Announces Board and Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is now offering a 3 ... who want to have their DarioHealth products reimbursed by ... agreements with partners across the U.S. who will be ... will supply and bill the customer,s insurance for their ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):